# US 2018/0313820 A1 · Stabilized bioactive peptides and methods of identification, synthesis, and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0313820 A1
- Document ID: US20180313820A1
- Status: Published application
- Kind: A1
- Application number: 16/030,564
- Filed: 2018-07-09
- Published: 2018-11-01
- Earliest claimed: 1998-10-13
- Assignees: Peptide BioSciences, Inc.
- Applicants: Peptide BioSciences, Inc.
- Inventors: Elliot Altman
- Web page: https://patentgrep.com/patent/US20180313820A1

## CPC

- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/14: Angiotensins: Related peptides
- C07K 14/195: from bacteria
- C07K 14/245: Escherichia (G)
- C07K 14/425: Zeins
- C07K 14/435: from animals; from humans
- C07K 14/43536: {from worms}
- C07K 14/43568: {from wasps}
- C07K 14/43572: {from bees}
- C07K 14/463: {from amphibians}
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 14/58: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- C07K 14/585: Calcitonins
- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K 14/605: Glucagons
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- C07K 14/62: Insulins
- C07K 14/63: Motilins
- C07K 14/645: Secretins
- C07K 14/655: Somatostatins
- C07K 14/665: derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/635: {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
- C12N 15/67: General methods for enhancing the expression
- C12N 15/72: Expression systems using regulatory sequences derived from the lac-operon
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5014: {for testing toxicity}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- C07K 2319/00: Fusion polypeptide
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.

## Claims

### Claim 1

A plurality of vectors, wherein each said vector comprises a nucleic acid sequence encoding a polypeptide, said polypeptide comprising a randomized peptide and a first stabilizing group coupled to one of said randomized peptide's termini, wherein said first stabilizing group lacks the capacity to participate in the formation of an intramolecular disulfide bond within the polypeptide, and wherein said plurality of vectors comprises at least two different vectors, each of said at least two vectors encoding a different polypeptide.

### Claim 2 (depends on 1)

The plurality of vectors of claim 1, wherein said polypeptide further comprises a second stabilizing group coupled to the other terminus of said randomized peptide.

### Claim 3 (depends on 1)

The plurality of vectors of claim 1, wherein each said vector further comprises a tightly regulable expression control sequence operably linked to said nucleic acid sequence encoding said polypeptide.

### Claim 4 (depends on 1)

The plurality of vectors of claim 1, wherein said plurality comprises at least 50 different vectors, each of said at least 50 vectors encoding a different polypeptide.

### Claim 5 (depends on 1)

The plurality of vectors of claim 1, wherein said plurality comprises at least 1×106 different vectors, each of said at least 1×106 vectors encoding a different polypeptide.

### Claim 6 (depends on 1)

A plurality of host cells collectively containing the plurality of vectors of claim 1.

### Claim 7 (depends on 6)

The host cells of claim 6, wherein said host cells are prokaryotic.

### Claim 8 (depends on 6)

The host cells of claim 6, wherein said host cells are eukaryotic.

### Claim 9

A method for selecting bioactive peptides, said method comprising:
a) expressing a plurality of stabilized polypeptides, wherein each said stabilized polypeptide is encoded by a different vector, and wherein each said stabilized polypeptide comprises a randomized peptide and a first stabilizing group coupled to one of said randomized peptide's termini, wherein said first stabilizing group lacks the capacity to participate in the formation of an intramolecular disulfide bond within the polypeptide, and wherein said plurality of stabilized polypeptide comprises at least two different polypeptides; and
b) screening each said stabilized polypeptide of said plurality for a bioactivity; and
c) selecting said bioactive peptides with said bioactivity.

### Claim 10 (depends on 9)

The method of claim 9, wherein said stabilized polypeptide further comprises a second stabilizing group coupled to the other terminus of said randomized peptide.

### Claim 11 (depends on 9)

The method of claim 9, wherein said plurality of stabilized polypeptides is expressed in eukaryotic cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein said eukaryotic cells are cancer cells and said bioactivity is a complete or partial inhibition of cell division, induction of apoptosis, or cell toxicity.

### Claim 13 (depends on 12)

The method of claim 12, said method further comprising testing said selected bioactive peptides for bioactivity in normal cells compared with said cancer cells.

### Claim 14 (depends on 11)

The method of claim 11, wherein said eukaryotic cells are stem cells or cord blood cells and said bioactivity is an increase in cell growth rate.
